Logo image of SNW.DE

SANOFI (SNW.DE) Stock Price, Forecast & Analysis

Europe - Frankfurt Stock Exchange - FRA:SNW - FR0000120578 - Common Stock

83.04 EUR
+0.78 (+0.95%)
Last: 12/30/2025, 7:00:00 PM

SNW.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap201.70B
Revenue(TTM)66.91B
Net Income(TTM)13.81B
Shares2.43B
Float2.17B
52 Week High110.82
52 Week Low76.43
Yearly Dividend3.79
Dividend Yield0%
EPS(TTM)7.6
PE10.93
Fwd PE9.77
Earnings (Next)01-28 2026-01-28/amc
IPO2002-07-01
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


SNW.DE short term performance overview.The bars show the price performance of SNW.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 1 -1 -2 -3 -4

SNW.DE long term performance overview.The bars show the price performance of SNW.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years -2 -4 -6 -8 -10

The current stock price of SNW.DE is 83.04 EUR. In the past month the price decreased by -2.97%. In the past year, price decreased by -10.91%.

SANOFI / SNW Daily stock chart

SNW.DE Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
1SAN.MI SANOFI 10.93 201.70B
SAN.PA SANOFI 10.88 200.93B
MRK.DE MERCK KGAA 14.37 53.30B
UCB.BR UCB SA 37.17 46.41B
UNC.DE UCB SA 36.84 46.00B
BAYN.DE BAYER AG-REG 6.93 36.36B
1BAYN.MI BAYER AG-REG 6.87 36.05B
REC.MI RECORDATI INDUSTRIA CHIMICA 24.64 10.15B
IPN.PA IPSEN 11.59 9.97B
TUB.BR FINANCIERE DE TUBIZE 100.48 9.30B
VIRP.PA VIRBAC SA 20.62 3.00B
DMP.DE DERMAPHARM HOLDING SE 18.3 2.12B

About SNW.DE

Company Profile

SNW logo image Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Company Info

SANOFI

46 Avenue de la Grande Armee

Paris ILE-DE-FRANCE FR

Employees: 82878

SNW Company Website

SNW Investor Relations

Phone: 33153774000

SANOFI / SNW.DE FAQ

Can you describe the business of SANOFI?

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.


What is the stock price of SANOFI today?

The current stock price of SNW.DE is 83.04 EUR. The price increased by 0.95% in the last trading session.


Does SANOFI pay dividends?

SNW.DE does not pay a dividend.


What is the ChartMill technical and fundamental rating of SNW stock?

SNW.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


Would investing in SANOFI be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SNW.DE.


What is the expected growth for SNW stock?

The Revenue of SANOFI (SNW.DE) is expected to decline by -0.09% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is SANOFI worth?

SANOFI (SNW.DE) has a market capitalization of 201.70B EUR. This makes SNW.DE a Mega Cap stock.


SNW.DE Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

SNW.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to SNW.DE. SNW.DE scores excellent on profitability, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SNW.DE Financial Highlights

Over the last trailing twelve months SNW.DE reported a non-GAAP Earnings per Share(EPS) of 7.6. The EPS decreased by -5.35% compared to the year before.


Industry RankSector Rank
PM (TTM) 20.35%
ROA 11.05%
ROE 19.73%
Debt/Equity 0.21
Chartmill High Growth Momentum
EPS Q2Q%1.75%
Sales Q2Q%-7.47%
EPS 1Y (TTM)-5.35%
Revenue 1Y (TTM)2.56%

SNW.DE Forecast & Estimates

29 analysts have analysed SNW.DE and the average price target is 106.47 EUR. This implies a price increase of 28.21% is expected in the next year compared to the current price of 83.04.

For the next year, analysts expect an EPS growth of 2.37% and a revenue growth -0.09% for SNW.DE


Analysts
Analysts81.38
Price Target106.47 (28.22%)
EPS Next Y2.37%
Revenue Next Year-0.09%

SNW.DE Ownership

Ownership
Inst Owners46.31%
Ins Owners0.01%
Short Float %N/A
Short RatioN/A